Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jan 5;129(1):9-10.
doi: 10.1182/blood-2016-11-749143.

Targeting CD19: the good, the bad, and CD81

Mireya Paulina Velasquez  1 , Stephen Gottschalk  1
Affiliations
Comment

Targeting CD19: the good, the bad, and CD81

Mireya Paulina Velasquez et al. Blood. .

Abstract

In this issue of Blood, Braig et al have identified a novel mechanism of CD19-targeted immune escape.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The Center for Cell and Gene Therapy at Baylor College of Medicine had a research collaboration with Celgene and Bluebird Bio, and currently has research collaborations with Cell Medica and Tessa Therapeutics. M.P.V. and S.G. have patents and/or patent applications in the fields of T-cell therapy and/or oncolytics.

Figures

None
Mechanisms of CD19-targeted immune escape. The B-cell coreceptor complex consists of CD19, CD21, CD81, and CD225 (for simplicity CD225 is omitted here). It is assembled in the rough endoplasmic reticulum (rER) and transported to the Golgi apparatus where the carbohydrate moieties are processed before being transported to the cell surface. Carbohydrate processing is indicated only for CD19 (light red: unprocessed carbohydrates; dark red: processed carbohydrates). (A) Normal processing and transport of CD19. (B) Splice variants resulting in loss of the extracellular domain of CD19. (C) Mutations resulting in a conformational change of the extracellular domain of CD19. (D) Loss of CD81 expression resulting in intracellular accumulation of CD19 with unprocessed carbohydrates. (E) Lineage switch resulting in transcriptional silencing of CD19 expression.
See this image and copyright information in PMC

Comment on

References

    1. Braig F, Brandt A, Goebeler M, et al. . Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129(1):100-104. - PubMed
    1. Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127(26):3312-3320. - PMC - PubMed
    1. May MB, Glode A. Blinatumomab: A novel, bispecific, T-cell engaging antibody. Am J Health Syst Pharm. 2016;73(1):e6-e13. - PubMed
    1. Sotillo E, Barrett DM, Black KL, et al. . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5(12):1282-1295. - PMC - PubMed
    1. Yu H, Sotillo E, Harrington C, et al. . Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma [published online ahead of print 25 October 2016]. Am J Hematol. doi:10.1002/ajh.24594. - PMC - PubMed